Tesamorelin
Neutral technical record and index of the peer-reviewed literature referencing Tesamorelin. For research use only — no human or veterinary use, benefit, or dosing information is provided.
Identity
| PubChem CID | 16137828 |
|---|---|
| CAS number | 218949-48-5 |
| Molecular formula | C221H366N72O67S |
| Molecular weight | 5136 g/mol |
| InChIKey | QBEPNUQJQWDYKU-BMGKTWPMSA-N |
What it is
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It belongs to the class of GHRH analogues. It is supplied as lyophilized material for research use only.
Mechanism (technical)
Tesamorelin has been studied for its action on GHRH receptors to stimulate endogenous growth hormone secretion and downstream IGF-1. In clinical research this mechanism has been investigated in relation to visceral and hepatic fat and lipid parameters. Cognitive endpoints have also been examined in the context of growth hormone axis stimulation.
Peer-reviewed literature
5 studies indexed · 5 human. Listed neutrally; outcome studies are indexed, not endorsed.
- Tesamorelin in HIV-associated lipodystrophy: meta-analysis of RCTsBadran AS, et al. · 2026 · Obes Res Clin Pract · meta-analysis · human
- Tesamorelin on visceral fat and liver fat in HIV patients: RCTStanley TL, et al. · 2014 · JAMA · RCT · human
- GHRH (tesamorelin) on cognition in MCI and healthy older adults: controlled trialBaker LD, et al. · 2012 · Arch Neurol · RCT · human
- Tesamorelin in HIV with excess abdominal fat: pooled phase 3 analysisFalutz J, et al. · 2010 · J Clin Endocrinol Metab · RCT · human
- Long-term safety and effects of tesamorelin in HIV with abdominal fatFalutz J, et al. · 2008 · AIDS · RCT · human
For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or dietary supplement. Sold to qualified researchers for laboratory research purposes only.